Current Report Filing (8-k)
October 26 2016 - 4:32PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM 8-K
CURRENT
REPORT Pursuant
to
Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of report (Date
of earliest event reported) :
October 26, 2016
SANGAMO
BIOSCIENCES, INC.
(Exact Name of Registrant as Specified in
Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
000-30171
|
68-0359556
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
501 Canal Blvd, Suite A100
|
Richmond, California 94804
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
(510)
970-6000
(Registrant’s Telephone Number, Including
Area Code)
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (
see
General Instruction A.2. below):
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02. Results of Operations and
Financial Condition.
On October 26, 2016,
Sangamo BioSciences, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2016. A copy
of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
|
(c)
|
Exhibits. The following material is filed as an exhibit
to this Current Report on Form 8-K:
|
Exhibit No.
|
99.1
|
Press Release Issued October 26, 2016.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
DATE: October 26, 2016
|
|
|
|
|
SANGAMO BIOSCIENCES, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ ALEXANDER MACRAE
|
|
|
|
Alexander Macrae, M.B., Ch.B., Ph.D.
|
|
|
President, Chief Executive Officer
|
Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Sep 2023 to Sep 2024